Literature DB >> 28286198

In-Hospital Mortality and Post-Transplantation Complications in Elderly Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Population-Based Study.

Larysa Sanchez1, Michael Sylvester2, Ricardo Parrondo2, Veronica Mariotti2, Jean Anderson Eloy3, Victor T Chang4.   

Abstract

Autologous hematopoietic stem cell transplantation (auto-HSCT) has improved survival in patients with multiple myeloma (MM) and is increasingly used in elderly patients. The aim of this study was to characterize and compare in-hospital complications and mortality after auto-HSCT in younger (< age 65) versus elderly (> age 65) MM patients utilizing the Nationwide Inpatient Sample. Over a 3-year period (2008 to 2010), 2209 patients with MM were admitted to US hospitals for auto-HSCT. The median age was 59 years, with 1650 patients (74.7%) younger than age 65 and 559 patients (25.3%) 65 or older. Overall, in-hospital mortality in MM patients after auto-HSCT was rare (1.5%) and there was no significant difference in mortality between elderly and younger patients. Elderly patients did have a significantly increased mean length of stay (18.6 days + 10.8 days [SD] versus 16.8 days + 7.2 days [SD], P < .001) and mean total hospital charges ($161,117 + $105,008 [SD] versus $151,192 + $78,342 [SD] , P = .018) compared with younger patients. Elderly patients were significantly more likely than younger patients to develop major in-hospital post-transplantation complications such as severe sepsis (odds ratio [OR], 2.70; 95% confidence interval [CI], 1.40 to 5.21; P = .003), septic shock (OR, 3.10; 95% CI, 1.43 to 6.71; P = .004), pneumonia (OR, 1.62; 95% CI, 1.06 to 2.46; P = .024), acute respiratory failure (OR, 3.44; 95% CI, 1.70 to 6.96; P = .001), endotracheal intubation requiring prolonged mechanical ventilation (OR, 2.19; 95% CI, 1.06 to 4.55; P = .035), acute renal failure (OR, 2.14; 95% CI, 1.38 to 3.33; P = .001), and cardiac arrhythmias (OR, 2.06; 95% CI, 1.52 to 2.79; P <.001). These data may help guide informed consent discussions and provide a focus for future studies to reduce treatment-related morbidity in elderly MM patients undergoing auto-HSCT.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. All rights reserved.

Entities:  

Keywords:  Autologous hematopoietic stem cell transplantation; Elderly; Multiple myeloma; Post-transplantation complications

Mesh:

Year:  2017        PMID: 28286198     DOI: 10.1016/j.bbmt.2017.03.012

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  8 in total

1.  Approach to the Older Adult With Multiple Myeloma.

Authors:  Roberto Mina; Sara Bringhen; Tanya M Wildes; Sonja Zweegman; Ashley E Rosko
Journal:  Am Soc Clin Oncol Educ Book       Date:  2019-05-17

Review 2.  Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies-Current Research and Clinical Approaches.

Authors:  Anastazja Poczta; Aneta Rogalska; Agnieszka Marczak
Journal:  J Clin Med       Date:  2021-04-23       Impact factor: 4.241

Review 3.  Pitfalls and Successes in Trials in Older Transplant Patients with Hematologic Malignancies.

Authors:  Aaron T Zhao; Anthony D Sung
Journal:  Curr Oncol Rep       Date:  2022-01-21       Impact factor: 5.075

4.  [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].

Authors:  H M Mo; Q Y Wu; D Y Han; R Liu; X Ma; P Zhou; K L Xu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-12-14

5.  Does Reinfusion of Stem Cell Products on Multiple Days Affect Engraftment?

Authors:  Şerife Solmaz Medeni; Doğuş Türkyılmaz; Celal Acar; Ömür Gökmen Sevindik; Faize Yüksel; Özden Pişkin; Mehmet Ali Özcan; Fatih Demirkan; Bülent Ündar; İnci Alacacıoğlu; Güner Hayri Özsan
Journal:  Turk J Haematol       Date:  2018-06-20       Impact factor: 1.831

Review 6.  Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects.

Authors:  Natasha Mupeta Kaweme; Geoffrey Joseph Changwe; Fuling Zhou
Journal:  Front Med (Lausanne)       Date:  2021-02-25

7.  Utilisation and outcomes of allogeneic hematopoietic cell transplantation in Ontario, Canada, and New York State, USA: a population-based retrospective cohort study.

Authors:  Samantha Aliza Hershenfeld; John Matelski; Vicki Ling; Michael Paterson; Matthew Cheung; Peter Cram
Journal:  BMJ Open       Date:  2020-10-31       Impact factor: 2.692

8.  Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma.

Authors:  Carolina Marini; Tânia Maia; Rui Bergantim; Jorge Pires; Eliana Aguiar; José Eduardo Guimarães; Fernanda Trigo
Journal:  Ann Hematol       Date:  2018-10-27       Impact factor: 3.673

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.